IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer

Launched by STATE UNIVERSITY OF NEW YORK AT BUFFALO · Jan 12, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer," is studying how patients with cancer who are receiving a specific type of treatment called Immune Checkpoint Inhibitors (ICI) manage their symptoms. The researchers want to understand the effects of different symptom management methods, including the use of cannabis, to help improve patient care and safety. Participants will complete online surveys and daily assessments over a year to compare the experiences of those who use cannabis with those who do not.

To join the study, participants need to be at least 21 years old, have a cancer diagnosis, and be planning to receive or currently receiving immunotherapy treatment. They should also experience pain but be able to spend less than half their day in bed or a chair. Participants must be fluent in English. However, those who have used synthetic cannabis or only Cannabidiol (CBD) in the past, or those with certain medical conditions, may not be eligible. If you decide to participate, you can expect to share your experiences and help contribute to valuable research that could improve how cancer symptoms are managed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult age of 21 years or older
• • cancer diagnosis and planning or using immunotherapy treatment,
• • pain and spend less than 50% in bed or chair
• • fluent in english language
• Exclusion Criteria:
• • use synthetic cannabis or only use Cannabidiol (CBD)
• • non users but used in the past 3 months
• • prior immunotherapy, Patients receiving immunosuppressants or organ transplant recipients.
• • Patients within 6 months of Hospice care.
• • Pain that limits movement to more than 50% of their day in bed or chair